Trials / Completed
CompletedNCT00616148
Efficacy of YKP3089 in Patients With Photosensitive Epilepsy
Pharmacodynamic Evaluation of YKP3089 in Epilepsy Patients With a Photo-induced Paroxysmal EEG-Response: Proof of Principle
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 11 (actual)
- Sponsor
- SK Life Science, Inc. · Industry
- Sex
- All
- Age
- 16 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to evaluate the ability of a single oral dose of YKP3089 to abolish or clearly reduce the IPS-induced photo-paroxysmal EEG response in photosensitive epilepsy patients, and to measure the onset and duration of the effect. Several cohorts will be used, to sequentially investigate different doses.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | YKP3089 | Oral dosage form |
| DRUG | Placebo |
Timeline
- Start date
- 2007-08-01
- Primary completion
- 2009-01-01
- Completion
- 2010-01-01
- First posted
- 2008-02-15
- Last updated
- 2014-01-31
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00616148. Inclusion in this directory is not an endorsement.